Aveo Pharmaceuticals diskutieren
Aveo Pharmaceuticals Inc.
WKN: A2P0CL / Symbol: AVEO / Name: Aveo Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
13,85 €
-1,91 %
(Vom Mitglied beendet)
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Researchs and develops cancer therapeutics
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need.
Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353.
The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need.
Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353.
The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
Nombre d'employés : 19 personnes.
(Vom Mitglied beendet)
Being optimistic about AVEO's mid- and long-term potential.
AVEO has a number of shots on deck relating to tivozanib, with possible other catalysts emerging from its nascent drug programs in development. In late 2018 and into 2019, here are some of the items
we can expect:
- Top line data from TIVO-3, which will inform the likelihood of getting approval for tivozanib in the US.
- Submission of a new drug application to the FDA for tivozanib.
- Updated
data from the expansion phase of TiNivo, giving a better sense of the
feasibility and efficacy of the tivozanib-nivolumab combination. - Updates on the development of ficlatuzumab, an HGF scavenger being studied in several solid tumors.
- Initiation of a phase 1 trial for CAN017, a HER3 antibody being developed in partnership with CANbridge Life Sciences in China.
(Laufzeit überschritten)
Boden
bei 0,50$ erreicht?!
(Stop Loss Kurs erreicht)
Secteur Recherche biotechnologique et médicale Agenda 01/04 | 19:00 Présentation
AVEO Pharmaceuticals, Inc. est une société biopharmaceutique. La plateforme de la société fournit des renseignements sur le cancer et les maladies connexes. Les produits candidats de la Société comprennent Tivozanib, Ficlatuzumab, AV-203 et AV-380. Tivozanib est un inhibiteur sélectif du facteur de croissance tyrosine kinase (VEGF TKI), un facteur de croissance vasculaire endothélial à longue demi-vie qui inhibe trois récepteurs VEGF. Tivozanib est conçu pour optimiser le blocage du VEGF tout en minimisant les toxicités hors cible. Le Ficlatuzumab est un anticorps inhibiteur du facteur de croissance des hépatocytes (HGF). AV-203 est un anticorps monoclonal anti-ErbB3 à affinité ErbB3. Ses études précliniques suggèrent que les niveaux de neuréguline1 (NRG1) prédisent l’activité antitumorale AV-203 dans les modèles précliniques. AV-380 est un anticorps monoclonal humanis inhibiteur de l'immunoglobuline G 1 (IgG1). AV-380 cible le facteur de différenciation de croissance 15 (GDF15).
Nombre d'employés
: 19 personnes.
(Vom Mitglied beendet)
(Vom Mitglied beendet)
Buy mit Kursziel 0,0
Buy mit Kursziel 1,0
Kursziel geändert auf 1,2
Buy Aveo Pharmaceuticals Inc.
Buy Aveo Pharmaceuticals Inc.
Buy Aveo Pharmaceuticals Inc.
Buy Aveo Pharmaceuticals Inc.
Sell Aveo Pharmaceuticals Inc.
Buy Aveo Pharmaceuticals Inc.
Neueste Beiträge
WatchMen in Biodexa Pharmaceuticals Plc diskutieren